Stockreport

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics [Yahoo! Finance]

AgeX Therapeutics, Inc.  (AGE) 
PDF Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the fourth quarter of 2024; IND submission to the FDA for the initiation of a [Read more]